Stock Analysis

What Do Analysts Think About AC Immune SA's (NASDAQ:ACIU) Future?

NasdaqGM:ACIU
Source: Shutterstock
The most recent earnings release AC Immune SA's (NASDAQ:ACIU) announced in December 2017 suggested company earnings became less negative compared to the previous year's level as a result of recent tailwinds Below, I've laid out key growth figures on how market analysts predict AC Immune's earnings growth outlook over the next few years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying drivers of earnings. View our latest analysis for AC Immune

Analysts' outlook for the coming year seems pessimistic, with earnings becoming even more negative, generating -CHF49.85M in 2019. Moreover, earnings are predicted to fall off in the following year, declining to -CHF56.20M in 2020 and -CHF98.18M in 2021.

NasdaqGM:ACIU Future Profit May 2nd 18
NasdaqGM:ACIU Future Profit May 2nd 18

Although it is useful to understand the growth year by year relative to today’s value, it may be more beneficial to analyze the rate at which the earnings are moving on average every year. The pro of this method is that we can get a bigger picture of the direction of AC Immune's earnings trajectory over the long run, irrespective of near term fluctuations, be more volatile. To calculate this rate, I've inserted a line of best fit through analyst consensus of forecasted earnings. The slope of this line is the rate of earnings growth, which in this case is 0.85%. This means that, we can anticipate AC Immune will grow its earnings by 0.85% every year for the next couple of years.

Advertisement

Next Steps:

For AC Immune, there are three relevant factors you should look at:

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does ACIU's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of ACIU? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

About NasdaqGM:ACIU

AC Immune

A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

Flawless balance sheet and good value.

Advertisement